Cavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study | October 05, 2018
~Totality of Data Demonstrates CX-8998 is Well Tolerated with Compelling Evidence of Efficacy Despite Missing Primary Endpoint Measured Using Central Video Rating~
Cavion to Announce Results of its Phase 2 Essential Tremor Clinical Trial | October 04, 2018
Cavion’s Results to be Featured as Late Breaker at International Congress of Parkinson’s Disease and Movement Disorders® in Hong Kong
Cavion Appoints Julia P. Gregory Executive Chair | September 11, 2018
Julia Gregory Brings to Cavion a Wealth of Experience and Deep Expertise in the Biopharma Industry
First Patient Enrolled in Cavion Multi-Center Phase 2 Clinical Trial in Epilepsy | March 20, 2018
Study to investigate new therapeutic approach for generalized epilepsy with absence seizures
Show More

Contact Us

Cavion

Charlottesville Office
600 East Water Street, Suite E
Charlottesville, VA 22902
(Please contact the Charlottesville Office for all accounting related communications)

Cambridge Office
1 Broadway, 14 FL
Cambridge, MA 02142

434.200.8442
info@cavionpharma.com
Directions